Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Della Porta, Uwe Platzbecker, Valeria Santini et al.|The Lancet Haematology|2024Cited by 50